Conference Call and Webcast: Q3/9M 2023 Financial Results
Replay Webcast (Audio and presentation).
Presentation for the Q3/9M 2023 results.
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
14.11.2023
voting rights
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
13.11.2023
voting rights
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
09.11.2023
voting rights
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
07.11.2023
voting rights
16
Nov
2023
You are now leaving the MorphoSys.com website. This link will take you to a different website. You are solely responsible for your interactions with that website.
Do you wish to proceed ?
Are you a U.S. resident? This portion of the MorphoSys website is intended for U.S. residents only. It is not for individuals living in Germany or other European Union member states.
Do you wish to proceed ?
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.
Are you a U.S. resident? This portion of the MorphoSys website is intended for U.S. residents only. It is not for individuals living in Germany or other European Union member states.